The Sputnik V vaccine showed a effectiveness 80% against coronavirus from the sixth to the eighth month after administering the second dose in a population study conducted in San Marino, the Russian Direct Investment Fund (RDIF) reported today.
The data are based on the number of infections by covid-19 in the European country in November this year on the basis of more than 18,600 people fully vaccinated with Sputnik V no less than 5 months before November. It is estimated that more than 70% of the adult population of this country received the Russian inoculant.
The rate of hospitalization with infection by covid-19 after the vaccination with Sputnik V in San Marino it was only 0.75 per 1,000 people during the entire mass immunization campaign in the country from February to November this year.
“Based on the analyzes we have done, adenovirus vaccines (such as the Sputnik or AstraZeneca) sustain elevated antibodies for longer than messenger RNA (such as Moderna or Pfizer), “Kirill Dimitriev, executive director of RDIF, said at a press conference today.
Dimitriev explained that based on the information from San Marino, while the effectiveness of the Sputnik remained at 80% after six months of second dose, “the effectiveness of the Pfizer vaccine fell to 29% and less against the Delta (variant) in the same time period. “
“We are facing a new rise in cases in Europe, what we see is that cases began to rise five months after the vaccination. We have to find solutions for this, “he said.
In this context, it indicated that “the Sputnik vaccine Light can be an ideal booster to increase the immune response for Sinopharm, AstraZeneca and other vaccines. “
As an example, the RDIF showed that in a study carried out in the Argentine province of Córdoba, the measurement of antibodies was 10 times higher in people who received the vaccine of Sinopharm combined with Sputnik V than those who had received the full schedule of the Chinese vaccine.
Sputnik V pioneered the heterogeneous scheme approach (a “vaccine cocktail”) as it uses human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component.
“This approach was shown to be successful in creating more durable immunity against coronavirus,” RDIF said in the statement.